Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

ROAR-A: Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer

A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).

Inclusion Criteria:

• Biopsy-verified anal cancer
• Eligible for curative intended radiotherapy
• Written and oral consent

Exclusion Criteria:

• Other malignant disease within the past 5 years (excluding basal cell carcinoma)